Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 225 of 563 entries
View as:

Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients

Phase: N/A Priority: Normal
NCT ID: NCT02845297 Org: User:
Start: 07/31/16 End: 12/31/22 Due: 12/31/23

Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06122480 Org: User:
Start: 05/21/24 End: 04/01/28 Due: 04/01/29

Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT00895180 Org: User:
Start: 07/31/10 End: 03/04/14 Due: 03/04/15

Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05103722 Org: User:
Start: 02/17/22 End: 04/01/24 Due: 04/01/25

Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01459614 Org: User:
Start: 11/30/11 End: 11/30/16 Due: 11/30/17

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

Phase: N/A Priority: Normal
NCT ID: NCT03043807 Org: User:
Start: 02/22/17 End: 10/17/22 Due: 10/17/23

Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02452008 Org: User:
Start: 05/03/16 End: 05/31/26 Due: 05/31/27

Study of PET Scans and Serotonin in Hot Flashes Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00249847 Org: User:
Start: 10/31/05 End: 04/30/08 Due: 04/30/09

Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT02224872 Org: User:
Start: 08/31/14 End: 12/31/21 Due: 12/31/22

Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06014255 Org: User:
Start: 02/16/24 End: 03/01/29 Due: 03/01/30

Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma

Phase: N/A Priority: Normal
NCT ID: NCT00631137 Org: User:
Start: 01/31/08 End: 09/30/08 Due: 09/30/09

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00134017 Org: User:
Start: 06/30/04 End: 02/28/10 Due: 02/28/11

Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound

Phase: N/A Priority: Normal
NCT ID: NCT02225925 Org: User:
Start: 10/01/14 End: 02/28/23 Due: 02/28/24

Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab

Phase: N/A Priority: Normal
NCT ID: NCT00946023 Org: User:
Start: 07/31/09 End: 07/17/13 Due: 07/17/14

Gene Therapy in Treating Patients With Recurrent Malignant Gliomas

Phase: N/A Priority: Normal
NCT ID: NCT00004041 Org: User:
Start: 02/25/99 End: 07/01/03 Due: 07/01/04

Chemoradiation or Brachytherapy for Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02017704 Org: User:
Start: 06/12/14 End: 01/31/23 Due: 01/31/24

Low Dose Radiation Therapy for Glioblastoma Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT01466686 Org: User:
Start: 09/30/12 End: 12/31/22 Due: 12/31/23

Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene

Phase: N/A Priority: Normal
NCT ID: NCT00303927 Org: User:
Start: 12/31/05 End: - Due: -

Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT00364364 Org: User:
Start: 05/31/07 End: 08/31/08 Due: 08/31/09

Collecting and Storing Samples of Blood From Patients With Pancreatic Cancer and Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT00898482 Org: User:
Start: 05/31/05 End: 06/30/11 Due: 06/30/12

Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT00486603 Org: User:
Start: 10/29/07 End: 01/31/14 Due: 01/31/15

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06941857 Org: User:
Start: 07/31/25 End: 07/31/30 Due: 07/31/31

Cyclophosphamide Plus Topotecan in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00003340 Org: User:
Start: 11/30/97 End: 02/29/00 Due: 02/28/01

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04117087 Org: User:
Start: 05/28/20 End: 08/08/25 Due: 08/08/26

A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT01088789 Org: User:
Start: 04/20/10 End: 07/31/25 Due: 07/31/26